Chaussain J L, Couprie C, Lacaille F, Simon D, Job J C
Hôpital Saint-Vincent-de-Paul, Paris, France.
Acta Paediatr Scand Suppl. 1988;347:38-43.
Treatment of precocious puberty of central origin is aimed at controlling the development of sexual characteristics and improving final height. Increased growth rate is one of the major clinical symptoms, accompanied by an even more marked advance in bone age. Medroxyprogesterone acetate and cyproterone acetate have provided almost satisfactory control of pubertal characteristics, but with accompanying adrenal insufficiency. The data with regard to growth and bone maturation are contradictory. LHRH analogues have recently become available, and provide good control of gonadotrophin secretion. In a series of 21 cases (13 girls, 8 boys), a significant decrease in growth rate was achieved in both sexes with an LHRH analogue, with a significant increase in the height age/bone age ratio; control of gonadal secretions was also obtained. These results are only preliminary, but provide hope that the final height of these children will be improved.
中枢性性早熟的治疗旨在控制性征发育并提高最终身高。生长速率加快是主要临床症状之一，同时骨龄有更明显的提前。醋酸甲羟孕酮和醋酸环丙孕酮对性征的控制几乎令人满意，但伴有肾上腺功能不全。关于生长和骨成熟的数据相互矛盾。促性腺激素释放激素（LHRH）类似物近来已可获得，且能很好地控制性腺激素分泌。在一组21例患者（13名女孩，8名男孩）中，使用LHRH类似物使两性的生长速率均显著下降，身高年龄/骨龄比值显著增加；性腺分泌也得到了控制。这些结果只是初步的，但给改善这些儿童的最终身高带来了希望。
